BioSpace News Archive

Global health company The Cigna Group reported strong first quarter 2023 results reflecting growth and focused execution across our diversified portfolio of businesses.

BiomX Inc. announced the second closing of its recently announced $7.5 million private placement investment.

Mallinckrodt plc is pleased to announce it has received an award from the NORD, recognizing it as an “Industry Innovator” for the creation of a treatment “to improve the lives of rare disease patients.” Mallinckrodt is being recognized for the U.S. FDA approval of TERLIVAZ® for injection for the treatment of adults with HRS with rapid reduction in kidney function.

Rapid Micro Biosystems, Inc. today announced its financial results for the first quarter ended March 31, 2023.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023.

WELL Health Technologies Corp. is pleased to announce the Company will release its First Quarter 2023 financial results for the period ended March 31, 2023, on Friday, May 12, 2023.

Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.

Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1.

Fulgent Genetics, Inc. today announced financial results for its first quarter ended March 31, 2023.

FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint.